MedTrace Logo

A Trial of Restrictive Versus Traditional Blood Transfusion Practices in Burn Patients

NCT01079247 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 347

Last updated 2023-08-04

No results posted yet for this study

Summary

The purpose of this study is to find out if burn injured patients do better receiving fewer blood transfusions than what is traditionally given. We traditionally provide blood transfusions to maintain a hemoglobin level, which is an indicator of the level of red blood cells that carry oxygen in your body, to above 10 g/dl (g/dl stands for grams per deciliter and is the standard measurement used to indicate the level of red blood cells in your blood). However, a preliminary study indicated that maintaining the hemoglobin level to above 7-8 g/dl with less blood transfusion, as compared to a hemoglobin level of 10 g/dl and above, would reduce the occurrence of blood infection, duration on the respirator and length of hospital stay, yet would achieve similar survival in both groups.

Conditions

  • Burn Injury

Interventions

OTHER

Restrictive transfusion threshold

maintain hemoglobin at 7-8 g/dL

OTHER

Liberal transfusion threshold

Maintain hemoglobin at 10-11 g/dL

Sponsors & Collaborators

  • U.S. Army Medical Research and Development Command

    collaborator FED

  • American Burn Association

    lead OTHER

Principal Investigators

  • Tina L Palmieri, MD · University of California, Davis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2016-09-28
Completion
2016-09-28

Countries

  • United States
  • Canada
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01079247 on ClinicalTrials.gov